<DOC>
	<DOCNO>NCT02785614</DOCNO>
	<brief_summary>The main objective evaluate pharmacokinetics comparative study single dose , multiple dose</brief_summary>
	<brief_title>PK Study Multi-dose Trazodone Hydrochloride Prolonged-released Tablets Healthy Chinese</brief_title>
	<detailed_description>Trial II Multiple dose , high specification ( 150mg ) pharmacokinetic study Trazodone Hydrochloride Prolonged Release Tablets ; 12 patient ( male female , half half ) . 2-period , 2 cross ( 2x2 ) crossover design use . screen 12 subject ( male female ) randomly divide two group ( II-1、II-2 ) , 3 male 3 female , give follow two different crossover treatment : trazodone hydrochloride prolonged-release tablet 150 mg per day 7 day T group , trazodone hydrochloride tablets 50mg 3 time per day 7 day R group . Wash-out period 14 day . Trial II . 2X2 design Group Period 1 Period 2 II -1 R T II -2 T R T group : subject provide trazodone hydrochloride prolonged-release tablet 150mg about8:00am day . Sampling site conduct day 1 , 5 , 6 , 7 administration period , blood sampling conduct 0.5 , 1.0 , 2.0 , 3.0 , 4.0 , 5.0 , 6.0 , 8.0 , 10.0 , 12.0 , 16.0 , 24.0 , 36.0 , 48.0 , 72.0h administration day 7 . R group : The subject receive 50mg trazodone hydrochloride tablet 50mg 3 time receive standard light breakfast 6:00am , standard meal 14:00 22:00 . Blood sample conduct day 1 , 5 , 6 , 7 first administration period , blood sampling conduct 0.5 , 1.0 , 1.5 , 2.0 , 3.0 , 4.0 , 6.0 , 8.0 ( second time administration ) , 8.5 , 9.0 , 9.5 , 10.0 , 11.0 , 12.0 , 14.0 , 16.0 ( third time administration ) , 16.5 , 17.0 , 17.5 , 18.0 , 19.0 , 20.0 , 22.0 , 24.0 , 36.0 , 48.0 , 72.0h administration day 7 . 5.0 mL venous blood forearm venous blood take venous indwell needle transfer heparin tube . After plasma separation store low temperature refrigerator .</detailed_description>
	<mesh_term>Trazodone</mesh_term>
	<criteria>Weight : subject be≥50 kg , BMI within 19~24 kg/m2 Blood pressure : SBP 90140mmHg，DBP 5090 mmHg； All subject understand trial well sign inform consent form participate study ; Subjects able communicate investigator well complete study accordance protocol . The baseline value safety evaluation index consider abnormal clinical significance investigator participate trial . A positive hepatitis B surface antigen result； A positive hepatitis C surface antigen result； A positive test HIV antibody syphilis testing； Any abnormality ECGs examination occur screen period first day administration : With history use drug inhibit induce liver metabolize drug within 1 month study initiation ; With history administrate drug ( prescription medicine , overthecounter drug Chinese herbal medicine ) within 2 week study initiation ; Past history heart disease , cardiac failure , myocardial infarction , angina , unknown cause arrhythmia , point swing pattern ventricular tachycardia , ventricular tachycardia , long QT syndrome long QT syndrome family history ( genetic proof close relative die heart disease ) ; History thyroid disease past history thyroid surgery ; History immune system disease ( thymus disease ) ； With surgery history within 6 month study initiation； History severe digestive disease ( gallbladder disease significant clinical significance , jaundice susceptive jaundice , hepatocellular adenoma , hepatic cavernous hemangioma liver disease ) ； With history gastrointestinal , liver renal disease ( matter cure ) affect drug absorption metabolism within 6 month study initiate History serve cardiocerebral vascular system , respiratory system , metabolic system nervous system diseases ; History hematological system disease , coagulation disorders； History tumor； Subjects hypokalemia hypocalcemia ( accord low limit value laboratory reference ranges； Life style : History alcohol addict within 6 month study Smoking &gt; 1 cigarette day last 3 month prior study ; History drug abuse take drug ( marihuana , cocaine , opium , benzodizepines , amphetamine , barbiturate , tricyclic antidepressant ) . History consumption excessive tea , coffee and/or caffeinated beverage ( 8 cups/day ) within period 2 day administration 8 day administration . History consumption grapefruit juice within period 2 day 8 day administration . Others： Subjects reject take effective contraceptive measure within time period inclusion 3 month administration ; Subjects allergic constitution , include allergic excipient ( microcrystalline cellulose , lactose , aerosil , sodium carboxymethyl starch , magnesium stearate ) product ; History participate clinical trial within 3 month study , participate clinical trial within time period inclusion one month last time visit ( last time administration ) ; History blood donation within 3 month prior study , within time period inclusion one month last time visit ( last time administration ) ; Subjects food allergy special diet requirement , follow standard diet ; Subjects , opinion investigator , participate study； The female subject eligible inclusion study meet follow criterion : With history consumption oral contraceptive within one month prior study； History longacting estrogen progesterone injection implant within 6 month prior study ; The bearingage female subject take appropriate contraceptive within 2 week prior study ; The bearingage female subject spouse willing take follow contraceptive measure , condom , copper intrauterine device within 3 month inclusion ; Subjects gestation period lactation period ; Subjects positive hCG test ; Single menstrual 80ml .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>